Impulse Dynamics推出安全性更高的血气分析系统

 
 
一种新型心衰治疗方法应用一种类似起搏器样的设备来加强心脏泵功能。

这种新设备包括脉冲发生器叫做Optimizer系统，能够将电信号传送至泵活动中心区域的心肌中，“欺骗”其产生更多的细胞内钙离子，从而增加心脏泵功能和收缩的活力。入选一项临床研究的患者正在接受这种设备的安全性和治疗效能的研究。

Optimizer系统包括一种程序化的植入脉冲发生器、便携式程序器、和两个右心室导联。起搏器侧重于调节心脏节律，Optimizer系统则以一项叫做心脏收缩调制(CCM)的新技术为基础。与起搏器信号不同，CCM信号是非刺激性的，意味着信号能够在绝对不应期传送，而且不会启动新的收缩。根据研究人员的说法，CCM信号触发心脏细胞内循环的钙离子的反应，能够提高心肌收缩力量，而不会增加总体工作负荷。

Beth Israel 医学中心(New York, NY, USA)心衰项目主任、在该医院进行的临床试验的首席研究员Jill Kalman医生说：“在减少工作负荷的同时，增加心脏泵功能的潜能，能够用于治疗III级或者IV级心脏功能衰竭患者，”

Optimizer系统是由Impulse Dynamics(USA)集团(Orangeburg, NY, USA)制造的， 这是Impulse Dynamics N.V. (Netherlands Antilles)公司的全资附属公司。

Safer Blood-Gas Analysis System
 
An innovative new treatment for heart failure uses a pacemaker-like device to help strengthen the heart’s pumping power.

The new device involves a pulse generator called the Optimizer system that delivers electrical signals to the heart muscle in the midst of its pumping action, fooling it into producing more intracellular calcium and thereby increasing the heart’s ability to pump and contract. Patients are now being enrolled in a study to investigate the safety and efficacy of the device.

The Optimizer system consists of a programmable implantable pulse generator, a portable programmer, and two right-ventricle leads. While pacemakers focus on modulating the heart’s rhythm, the Optimizer system is based on new technology known as cardiac contractility modulation (CCM). Unlike pacemaker signals, CCM signals are non-excitatory, meaning they are delivered during the absolute refractory period and therefore cannot initiate a new contraction. According to the investigators, the result is that CCM signals trigger a response in the calcium that is cycling within the heart cells in a way that improves the strength of the heart muscle’s contraction, without adding to its overall workload.

“The potential to improve the heart’s pumping ability while decreasing its workload would present a significant development in treating patients with class III or class IV heart failure,” observed Jill Kalman, M.D., director of the heart failure program at Beth Israel Medical Center (New York, NY, USA) and lead investigator of the trial at the hospital.

The Optimizer system is manufactured by Impulse Dynamics (USA), Inc. (Orangeburg, NY, USA), a wholly owned subsidiary of Impulse Dynamics N.V. (Netherlands Antilles).